Loading
Phentermine / Childhood Obesity · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 2b randomized, double-blind, placebo-controlled trial (NCT07282340) designed to evaluate phentermine 16 mg daily versus placebo in adolescents (aged 12–<18) with obesity, with a primary endpoint of percent change in BMI at week 52. No results are posted in this registry record; the study is currently recruiting and outcome data are not yet available.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Childhood Obesity; age from 12 Years; to 17 Years. Intervention: Phentermine 16 mg Group. Compared with: Placebo Group — Placebo Comparator. n = 240. 6 sites: United States.
This is an active Phase 2b randomized, double-blind, placebo-controlled trial (NCT07282340) designed to evaluate phentermine 16 mg daily versus placebo in adolescents (aged 12–<18) with obesity, with a primary endpoint of percent change in BMI at week 52. No results are posted in this registry record; the study is currently recruiting and outcome data are not yet available.
This is a registry record only; no efficacy, safety, or outcome results have been posted or are reported in this source. No safety data, adverse event rates, or withdrawal data are available from this registry record.
The source did not state who this applies to in practice.
This is an active recruitment registry record for a Phase 2b trial with no results posted; it describes planned design and enrollment only, not clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07282340). This is a study registration, not published results. Lead sponsor: Russell McCulloh, MD. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 240 participants (ESTIMATED). Conditions: Childhood Obesity. Interventions: DRUG: Phentermine; DRUG: Placebo. Primary outcome measures: Percent Change in BMI from Baseline at Week 52 , 52 weeks. Brief summary: PhITT is a Phase IIb, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of phentermine (16 mg daily) in adolescents aged 12 to \<18 years with obesity. Conducted across approximately 10 sites within the IDeA States Pediatric Clinical Trials Network (ISPCTN), the study aims to enroll up to 240 participants and then randomize up to 198 who meet eligibility criteria, randomized in a 2:1 ratio to phentermine or placebo over a 52-week treatment period, followed by a 2-week withdrawal assessment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.